GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:000758421 | Liver | HCC | response to nutrient | 111/7958 | 174/18723 | 1.10e-08 | 2.73e-07 | 111 |
GO:000963622 | Liver | HCC | response to toxic substance | 153/7958 | 262/18723 | 1.37e-07 | 2.58e-06 | 153 |
GO:000941022 | Liver | HCC | response to xenobiotic stimulus | 248/7958 | 462/18723 | 6.47e-07 | 1.02e-05 | 248 |
GO:000166612 | Liver | HCC | response to hypoxia | 172/7958 | 307/18723 | 1.06e-06 | 1.59e-05 | 172 |
GO:003629312 | Liver | HCC | response to decreased oxygen levels | 179/7958 | 322/18723 | 1.29e-06 | 1.87e-05 | 179 |
GO:007048212 | Liver | HCC | response to oxygen levels | 191/7958 | 347/18723 | 1.42e-06 | 2.03e-05 | 191 |
GO:004578711 | Liver | HCC | positive regulation of cell cycle | 172/7958 | 313/18723 | 5.29e-06 | 6.58e-05 | 172 |
GO:000762321 | Liver | HCC | circadian rhythm | 117/7958 | 210/18723 | 7.29e-05 | 6.54e-04 | 117 |
GO:00323552 | Liver | HCC | response to estradiol | 81/7958 | 141/18723 | 2.39e-04 | 1.79e-03 | 81 |
GO:001407421 | Liver | HCC | response to purine-containing compound | 84/7958 | 148/18723 | 3.19e-04 | 2.26e-03 | 84 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:004668321 | Liver | HCC | response to organophosphorus | 73/7958 | 131/18723 | 1.52e-03 | 8.05e-03 | 73 |
GO:00459263 | Liver | HCC | negative regulation of growth | 129/7958 | 249/18723 | 1.81e-03 | 9.37e-03 | 129 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC6A4 | SNV | Missense_Mutation | | c.352C>T | p.Leu118Phe | p.L118F | P31645 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
SLC6A4 | SNV | Missense_Mutation | rs774795329 | c.1316N>T | p.Thr439Met | p.T439M | P31645 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
SLC6A4 | SNV | Missense_Mutation | rs774252706 | c.38N>T | p.Ser13Leu | p.S13L | P31645 | protein_coding | tolerated_low_confidence(0.2) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC6A4 | SNV | Missense_Mutation | | c.386N>A | p.Gly129Glu | p.G129E | P31645 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
SLC6A4 | SNV | Missense_Mutation | | c.221T>G | p.Leu74Arg | p.L74R | P31645 | protein_coding | tolerated(0.54) | benign(0.003) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
SLC6A4 | SNV | Missense_Mutation | | c.1159N>A | p.Ala387Thr | p.A387T | P31645 | protein_coding | deleterious(0) | probably_damaging(0.938) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | novel | c.540G>A | p.Met180Ile | p.M180I | P31645 | protein_coding | tolerated(1) | benign(0) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
SLC6A4 | insertion | Nonsense_Mutation | novel | c.1569_1570insTGACAAAGTGAGACT | p.Arg523_Asp524insTer | p.R523_D524ins* | P31645 | protein_coding | | | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
SLC6A4 | insertion | Nonsense_Mutation | novel | c.1856_1857insTATCAGATACCAATGATCATACCAACAGA | p.Glu619AspfsTer6 | p.E619Dfs*6 | P31645 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC6A4 | SNV | Missense_Mutation | | c.1124N>T | p.Ser375Leu | p.S375L | P31645 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-C5-A2LT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | DULOXETINE | DULOXETINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | buprenorphine | BUPRENORPHINE | 29333880 |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178104007 | LEVOMILNACIPRAN | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | berberine | BERBERINE | 21647174 |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | inhibitor | 178103894 | VENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | DESVENLAFAXINE | DESVENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | ethanol | ALCOHOL | 31595439 |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | VENLAFAXINE | VENLAFAXINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | AMOXAPINE | AMOXAPINE | |
6532 | SLC6A4 | TRANSPORTER, DRUGGABLE GENOME | | AMOXAPINE | AMOXAPINE | |